Sana Biotechnology, Inc. Shareholders' Equity
Sana Biotechnology, Inc. (SANA) had Shareholders' Equity of $154.57 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-10
- 2026-06-30: Stockholders' Equity Attributable to Parent $154.57M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $119.24M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $160.88M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $195.31M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $154.57M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $119.24M 10-Q · filed 2026-08-10 |
| 2025-12-31 | $160.88M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $195.31M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $122.56M 10-Q · filed 2026-08-10 |
| 2025-03-31 | $209.08M 10-Q · filed 2026-08-10 |
| 2024-12-31 | $250.50M 10-Q · filed 2026-08-10 |
| 2024-09-30 | $292.48M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $339.65M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $375.14M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $287.51M 10-K · filed 2026-03-03 |
| 2023-09-30 | $365.85M 10-Q · filed 2024-11-08 |
| 2023-06-30 | $355.03M 10-Q · filed 2024-11-08 |
| 2023-03-31 | $428.26M 10-Q · filed 2024-11-08 |
| 2022-12-31 | $499.31M 10-K · filed 2026-03-03 |
| 2022-09-30 | $566.02M 10-Q · filed 2023-11-08 |
| 2022-06-30 | $639.50M 10-Q · filed 2023-11-08 |
| 2022-03-31 | $701.65M 10-Q · filed 2023-11-08 |
| 2021-12-31 | $728.50M 10-K · filed 2025-03-17 |
| 2021-09-30 | $830.09M 10-Q · filed 2022-11-02 |
| 2021-06-30 | $905.90M 10-Q · filed 2022-11-02 |
| 2021-03-31 | $881.98M 10-Q · filed 2022-11-02 |
| 2020-12-31 | -$421.18M 10-K · filed 2024-02-29 |
| 2020-09-30 | -$311.18M 10-Q · filed 2021-11-08 |
| 2020-06-30 | -$260.93M 10-Q · filed 2021-11-08 |
| 2020-03-31 | -$174.67M 10-Q · filed 2021-11-08 |
| 2019-12-31 | -$142.54M 10-K · filed 2023-03-16 |
| 2018-12-31 | -$13.19M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |